CASI Pharmaceuticals: Business Overview, Financials & Competitive Analysis
CASI Pharmaceuticals scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biopharma with differentiated anti-CD38 asset could deliver substantial value if CID-103 advances successfully through trials, but near-term capital requirements and clinical development risks warrant cautious positioning. CASI shows promise with a lead candidate (CID-103) in active development and analyst support (Strong Buy rating with $4.0 price target), but faces.
What is CASI Pharmaceuticals's industry? CASI Pharmaceuticals (casipharmaceuticals.com) operates in Biopharmaceuticals / Monoclonal Antibody Development. AskCyborg classifies CASI Pharmaceuticals under Biopharmaceuticals / Monoclonal Antibody Development in its company registry.
CASI Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. The company is d...
Cyborg Score thesis
Clinical-stage biopharma with differentiated anti-CD38 asset could deliver substantial value if CID-103 advances successfully...
Read the full analyst-debate transcript →Get the Latest CASI Pharmaceuticals Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCASI Pharmaceuticals Overview
Pro stress-test →CASI Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. The company is developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases.
Strategic Profile
Pro stress-test →The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. CASI is transitioning toward clinical-stage focus on CID-103, a potentially best-in-class anti-CD38 candidate with significant unmet medical need in transplant rejection and immunological indications, positioning it at an inflection point in its product development.
Competitive Landscape
Pro stress-test →CASI operates in the anti-CD38 monoclonal antibody space competing against established players and other clinical-stage programs. The company differentiates through a unique CD38 epitope targeting mechanism. Key competitive areas include solid tumor oncology and immunological conditions like transplant rejection, where limited approved treatment options exist.
Industry Context
CASI Pharmaceuticals operates in Biopharmaceuticals / Monoclonal Antibody Development.
Key facts
Founded: 2023 · Headquarters: South San Francisco, United States · Employees: 233